Some postmenopausal ladies with early stage breast most cancers can safely forgo chemotherapy, in accordance with a nationwide research from the director of the Glenn Household Breast Heart on the Winship Most cancers Institute of Emory College. The research’s lead writer, Winship investigator and breast oncologist Kevin Kalinsky, referred to as the findings “practice-changing” and stated they’ll permit sure postmenopausal ladies to be spared pointless chemotherapy and depend on hormone remedy as a substitute.
The RxPONDER medical trial checked out ladies with hormone receptor (HR)-positive, human epidermal progress issue receptor 2 (HER2)-negative breast most cancers that had unfold to a restricted variety of lymph nodes. It thought-about ladies with a low threat of recurrence, as measured by an Oncotype rating. Whereas pre-menopausal ladies benefitted from chemotherapy, post-menopausal ladies didn’t, the research discovered.
For extra on RxPONDER research, see:
View Dr. Kalinsky’s doctor profile:
Find out about breast most cancers care at Winship Most cancers Institute of Emory College, go to